MAPT and Alzheimer disease: A combined assay to measure levels of tau phosphorylated at threonine 181 in plasma for use in conjunction with a plasma neurofilament light chain assay to discriminate between AD and non-AD neurodegenerative dementias, for example CTE, is under development (76, 77).